Q2 FY2026 EarningsQ2 FY26 results significantly exceeded consensus expectations on the top line, reporting revenue of $1.01M vs. $0.42M expected. Despite a net loss, EPS (GAAP) of -$0.36 beat the -$0.39 consensus, driven by aggressive cost reductions in R&D (down 78% YoY) and G&A (down 31% YoY). Management narrowed the FY26 cash guidance to $259M to account for $12M in recent share repurchases, while maintaining a strong balance sheet with $289.1M in cash and no debt.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Prothena(PRTA) the Revenue is 1.01 M (-77.15%), Beat estimate;the EBIT is -21.1 M (+75.06%), Beat estimate;the EPS is -0.36 (+84.62%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B77.15%
0.00B90.46%
+0.00B13.31%
EBITExceed expectations
-0.02B75.06%
-0.02B74.37%
+0.00B0.69%
EPSExceed expectations
-0.3684.62%
-0.3983.33%
+0.03001.29%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf